Sporadic inclusion body myositis (sIBM) is a common age-related inflammatory myopathy characterized by the presence of intracellular inclusions that contain the amyloid-β (Aβ) peptide, a derivative of the amyloid precursor protein (APP). Aβ is believed to cause Alzheimer's disease (AD), suggesting that a link may exist between the two diseases. If AD and sIBM are linked, then treatments that lower Aβ in brain may prove useful for sIBM. To test this hypothesis, transgenic mice that overexpress APP in skeletal muscle were treated for 6 months with a variety of nonsteroidal anti-inflammatory drugs (NSAIDs; naproxen, ibuprofen, carprofen or R-flurbiprofen), a subset of which reduce Aβ in brain and cultured cells. Only ibuprofen lowered Aβ in muscle, and this was not accompanied by corresponding improvements in phenotype. These results indicate that the effects of NSAIDs in the brain may be different from other tissues and that Aβ alone cannot account for skeletal muscle dysfunction in these mice.
Introduction
Sporadic inclusion body myositis (sIBM) is the most common degenerative skeletal muscle disease affecting persons over the age of 50 (Flachenecker, 2006) . sIBM pathology includes characteristic rimmed vacuoles, accumulations of filamentous proteins (Askanas and Engel, 2006), inflammation (Dalakas, 2006a) , and mitochondrial abnormalities (Oldfors et al., 2006) . Although widespread inflammation is an extremely prominent feature of sIBM pathology, various forms of immune suppression have failed to halt the progression of the disease, suggesting that sIBM is driven by a primary degenerative process (Dalakas, 2006b) . Currently, there are no effective therapeutics for sIBM.
Alzheimer's disease (AD) is the major neurodegenerative disorder affecting the elderly (Roberson and Mucke, 2006) . Although the overall pathology of AD is complex, the disease is believed to be caused by the production and deposition of the 42 amino acid amyloid-β peptide (Aβ42), which is proteolytically derived from the amyloid-β precursor protein (APP) (Hardy, 2006; Wilquet and De Strooper, 2004) . It was demonstrated more than a decade ago that both Aβ and an abnormally phosphorylated form of tau are major components of the intracellular inclusions found in the muscle tissue of sIBM patients (Askanas and Engel, 2006) . Thus, the proteinaceous deposits in both AD and sIBM share the same characteristic components, raising the intriguing possibility that AD and sIBM may be connected at some level. Unfortunately, there are no clinical studies examining the comorbidity of the two diseases. Further, the importance of Aβ in AD is backed by strong genetic evidence, whereas the role of Aβ in sIBM primarily rests on descriptive studies of human pathology.
Although a comprehensive clinical comparison of the two diseases is not available, good evidence for a role of APP and/or Aβ in the pathogenesis of sIBM comes from several other sources. Although overexpression is not likely required for disease, APP is often overexpressed in the disease state (Li et al., 2006; Sarkozi et al., 1993) . The in vitro overexpression of APP in muscle cells leads to a range of degenerative changes resembling various facets of sIBM pathology (Askanas et al., 1996) , including the induced overexpression of other proteins found within the inclusion bodies (Wojcik et al., 2006) . The overexpression of a C-terminal fragment (CTFβ) of APP (Fukuchi et al., 1998; Jin et al., 1998) or the full-length APP molecule itself (Moussa et al., 2006; Sugarman et al., 2002 ) also leads to the manifestation of vacuolar changes, centric nuclei, lymphocytic infiltration, and amyloid deposition in skeletal muscle. This is accelerated by the introduction of a presenilin 1 (PS1) mutation that increases the relative amount of Aβ42, and the muscle weakening phenotype is highly correlated with increasing amounts of this peptide (Kitazawa et al., 2006) . The fact that the overexpression of APP recapitulates many facets of the disease phenotype in mice and that this phenotype is worsened by a selective augmentation of the Neurobiology of Disease 39 (2010) [449] [450] [451] [452] [453] [454] [455] [456] 
